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The effect of extracorporeal blood purification on clinical
outcomes in sepsis is assumed to be related to modulation of
plasma cytokine concentrations. To test this hypothesis
directly, we treated rats that had a cecal ligation followed by
puncture (a standard model of sepsis) with a modest dose of
extracorporeal blood purification that did not result in acute
changes in a panel of common cytokines associated with
inflammation (TNF-a, IL-1b, IL-6, and IL-10). Pre- and
immediate post-treatment levels of these cytokines were
unchanged compared to the sham therapy of extracorporeal
circulation without blood purifying sorbent. The overall
survival to 7 days, however, was significantly better in
animals that received extracorporeal blood purification
compared to those with a sham procedure. This panel of
common plasma cytokines along with alanine
aminotransferase and creatinine was significantly lower 72h
following extracorporeal blood purification compared to
sham-treated rats. Thus, the effects of this procedure on
organ function and survival do not appear to be due solely to
immediate changes in the usual measured circulating
cytokines. These results may have important implications for
the design and conduct of future trials in sepsis including
defining alternative targets for extracorporeal blood
purification and other therapies.
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Sepsis is the leading cause of death for patients in intensive
care units.1,2 The inflammatory response to infection or
injury includes the expression of numerous cell-associated
and soluble molecules, and it is believed that this systemic
inflammation is in large part responsible for the develop-
ment of shock and subsequent multiorgan injury.3–5 Multiple
attempts have been made, and many others are currently
underway, to block the specific mediators of coagula-
tion/inflammatory response. However, these attempts have
had relatively little impact on overall outcome in the critically
ill.6 In a recent large observational study of community-
acquired sepsis secondary to pneumonia, we observed the
highest risk of death in patients with increased activation
of both proinflammatory and anti-inflammatory cytokines.7
Thus, broad-spectrum immune-modulating therapies using
drugs or devices have been sought to reduce multiple inflam-
matory mediators in sepsis.
Extracorporeal blood purification (EBP) techniques such as
hemofiltration or apheresis have been proposed for many
years as possible strategies to modulate the multiple inflam-
matory mediators in the same way that hemodialysis is
effective in removing multiple uremic toxins.8 However,
although preclinical9–12 and even early clinical studies13–15
have shown great promise, multicenter randomized clinical
trials have been disappointing.16,17 Importantly, development
and testing of EBP for sepsis have been predicated on the
assumption that cytokine levels must be altered for the therapy
to be effective, and so far clinical trials have failed to result in
significant changes in circulating cytokine levels,16,17 whereas
preclinical studies have shown robust effects.9–12 This failure
has led to the development of novel EBP techniques such as
high-volume hemofiltration,18 combined plasma filtration and
adsorption,19 and hemoadsorption.20 However, the assump-
tion that EBP works through changes in inflammatory
cytokines has never been satisfactorily tested. If this relation-
ship can be proven, it will help guide future work in this area.
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2012 International Society of Nephrology
Received 8 October 2010; revised 8 July 2011; accepted 19 July 2011;
published online 14 September 2011
Correspondence: John A. Kellum, Department of Critical Care Medicine,
University of Pittsburgh, 604 Scaife Hall, 3550 Terrace Street, Pittsburgh,
Pennsylvania 15261, USA. E-mail: kellumja@ccm.upmc.edu
4These authors contributed equally to this work.
Kidney International (2012) 81, 363–369 363
We have previously shown that EBP by hemoadsorption
using CytoSorb beads (CytoSorbents, Monmouth Junction,
NJ) has the capacity to alter circulating cytokine levels and
improve survival in experimental endotoxemia10 and cecal
ligation puncture (CLP)-induced sepsis12 in animals. How-
ever, these studies were carried out in highly lethal models
of sepsis (LD90) using very intensive therapy resulting in
significant removal of cytokines, and examining only short-
term (1 day) survival. Such extreme conditions are rarely
encountered clinically21 and may not represent typical
human sepsis.
Thus, in this study, we sought to test blood purification in
a more realistic setting and evaluate long-term (7 days)
survival as an end point. We also scaled our intervention to
the point that cytokine levels were no longer reduced, in the
short term, by the treatment. Finally, we examined organ
function and sought to explore possible mechanisms whereby
EBP is effective.
RESULTS
Blood purification did not alter plasma cytokine
concentrations acutely
The most commonly measured cytokines in sepsis, tumor
necrosis factor-a (TNF-a), interleukin (IL)-1b, IL-6, and IL-10,
were measured. Differences in these circulating plasma cytokine
concentrations for septic rats treated with EBP, sham, or
control are shown in Figure 1. Baseline values (18 h after CLP)
were not different among the three groups for any cytokine.
Plasma cytokine concentrations remained constant immedi-
ately after treatment and were not different between groups.
However, at later time points (48 and 72 h) and long after
intervention, cytokine concentrations were significantly lower
in the EBP group (Figure 1). The concentrations of TNF-a,
IL-1b, IL-6, and IL-10 were all significantly lower in the
EBP group 48 h after treatment (72 h after CLP). Cytokine
concentrations in the sham group were not significantly
different from controls.
Blood purification improved 1-week survival despite not
affecting early cytokine levels
Survival was analyzed until 7 days after CLP. Survival time
was greater with EBP compared with sham (hazard ratio:
0.48, P¼ 0.02) and control (hazard ratio: 0.77, P¼ 0.04;
Figure 2). Survival was not statistically different between
sham and control animals.
Effects of EBP on high-mobility group box 1 (HMGB-1) and on
organ function
Figure 3 shows the effect of EBP on HMGB-1 in blood.
Plasma HMGB-1 increased after CLP (4.34 vs. 17.29 in sham-
treated animals, Po0.05). EBP attenuated this increase.
By 48 h after treatment, the difference of HMGB-1 concen-
trations between the two groups was statistically significant
(EBP, 8.65 ng/ml vs. sham, 17.29 ng/ml, Po0.05).
We monitored liver function using alanine aminotrans-
ferase (ALT) and used serum creatinine to monitor renal
function. Figure 4 demonstrates the effects of EBP on ALT
and creatinine. Before treatment (18 h after CLP), mean ALT
values were similar in both groups. However, by 48 h after
treatment, the ALT was significantly lower in the EBP-treated
rats (23.13 vs. 57.07 IU/l, Po0.05). Changes in serum
creatinine were similar (0.68 vs. 1.72mg/dl, 48 h after
treatment, Po0.05). Histopathology (liver and kidney) was
consistent with the biochemical changes (Figure 4).
HMGB-1 levels and organ function in control animals were
not different from sham-treated animals at any time point.
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Figure 1 | Effects of extracorporeal blood purification (EBP) in
cytokine removal. Plasma cytokine levels over time are shown
for cecal ligation puncture (CLP) control, EBP, and sham-treated
animals. All data were natural log transformed (ln pg/ml) and
expressed as mean±s.e.m. Each panel shows a separate cytokine:
(a) tumor necrosis factor-a (TNF-a); (b) interleukin (IL)-6; (c) IL-1b;
and (d) IL-10. *Po0.05, vs. EBP at the same time points; #Po0.05,
vs. the baseline (at 18 h) in the same groups.
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Figure 2 | Effects of extracorporeal blood purification (EBP) on
1-week survival. Survival time (days) was observed from the start
of cecal ligation puncture (CLP). P¼ 0.02, EBP vs. sham. P¼ 0.04,
EBP vs. CLP control.
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Effects of exchange transfusions between EBP and
sham-treated rats
To help elucidate the mechanism whereby EBP improved
survival, we carried out a separate set of experiments in
which we performed exchange transfusions between EBP and
sham-treated rats immediately after treatment. Our results
showed a near matching of IL-6 levels (Figure 5) and survival
(Figure 6) between the two groups.
Effects of EBP on nuclear factor-jB (NF-jB) activation in
circulating leukocytes
To further explore whether EBP affects key cellular elements
in the production of cytokines, we measured NF-kB
activation in circulating leukocytes. NF-kB activation in
both polymorphonuclear neutrophils (PMNs) and mono-
cytes was reduced with EBP compared with sham treatment.
However, only the NF-kB decrease in PMNs was statistically
significant (Figure 7).
DISCUSSION
This study demonstrates first and foremost that the effects of
EBP are not explained solely by removal of common sepsis
cytokines from the plasma space. CytoSorb, an adsorbent
polymer, was found to attenuate late increases in inflamma-
tory mediators (cytokines and HMGB-1), improve organ
(liver and renal) function, and improve long-term (1 week)
survival in this rodent model of CLP-induced sepsis despite
not having significant effects on early cytokine levels. These
results are important because current efforts to develop and
test blood purification strategies for the treatment of sepsis
are predicated on the removal of cytokines. Our results
indicate that clinical effects of blood purification are not
limited to and do not require short-term changes in
circulating levels of the most commonly measured inflam-
matory cytokines. This finding has important implications
for the design of clinical trials of EBP for treatment of
patients with severe sepsis.
Despite failing to modulate cytokines acutely, our results
are consistent with those of our previous studies in acute
lethal sepsis models using endotoxin injection10 and CLP.12
However, this study is significantly closer to the clinical
scenario because it was designed to evaluate long-term
(1 week) survival in a model of sepsis that resulted in a
mortality rate similar to that observed clinically. We also
began therapy only after animals began to manifest sepsis as
evidenced by clinical signs and inflammatory mediator levels.
Finally, we used a smaller device (1ml) in comparison with
our previous studies. On the basis of body weight, this 1ml
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Figure 3 | Effects of extracorporeal blood purification (EBP) on
high-mobility group box 1 (HMGB-1). Plasma HMGB-1 levels are
shown over time (mean±s.e.m., ng/ml). *Po0.05, vs. EBP at
the same time points; #Po0.05, vs. the baseline (at 18 h) in
the same groups.
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Figure 4 | Effects of extracorporeal blood purification (EBP) on
organ function. Shown are plasma alanine aminotransferase
(ALT; IU/l) and creatinine (Cr; mean±s.e.m., mg/dl). *Po0.05, vs.
EBP at the same time points; #Po0.05, vs. the baseline (at 18 h) in
the same groups. (a) Plasma ALT. (b) Liver histology from EBP
showing mild swelling of hepatocytes. (c) Liver histology slice
from sham showing moderate to severe swelling of hepatocytes
with focal piecemeal necrosis. (d) Plasma creatinine. (e) Kidney
histology from EBP showing vacuolization in tubules; however,
these changes are milder compared with sham (f). (f) Kidney
histology from sham showing significant vacuolization in tubules.
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device in a 500 g rat would translate to a 140ml device in a
70 kg man, which is smaller than a standard hemodialysis
filter.
We used CLP-induced sepsis to test our device because it
resembles clinical sepsis21 where the infection spreads from a
local focus to generalized septic shock.21–23 The peritonitis
that ensues is polymicrobial (for example, Escherichia coli,
Proteus mirabilis, Enterococcus, Bacteroides fragilis, and so on)
and resembles human disease. Animals appear normal
for B10 h after CLP, and then begin to demonstrate a
hyperdynamic, hyperinsulinemic, hypermetabolic state along
with high blood lactate. Later, CLP-induced sepsis may
become hypodynamic24 and the cytokine response is fully
activated by 16–18 h. The mortality of CLP can also be
adjusted by varying the length of the cecum ligation and the
size and number of puncture sites.23–25 It was established that
the percentage of cecum ligated was the principal deter-
minant of mortality, with 90% mortality in 2 days if 433%
of the cecum was ligated with three punctures using a
20-gauge needle in our previous model.12,24 In this study, we
ligated 25% of the cecum and punctured two times with a
20-gauge needle. In our experience, using older rats, this
model resulted in a 50–60% mortality at 1 week with renal
and liver injury. We chose IL-1b, TNF-a, IL-6, and IL-10 as
the target markers, as these markers represent common
pro- and anti-inflammatory mediators. These markers are
easily detected in this model. Moreover, changes of these
markers are related to the prognosis in septic patients.7
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Figure 5 | Effects of exchange transfusion on interleukin-6
(IL-6). Shown are plasma IL-6 levels over time for each of the four
groups. Data were natural log transformed (ln pg/ml) and
expressed as mean±s.e.m. EBP, extracorporeal blood purification
group; EBP to sham, sham animals received blood from the EBP
animals; Sham, sham group; Sham to EBP, EBP animals received
blood from the sham animals. IL-6 at 72 h in sham group was
significantly higher than at baseline (18 h), and IL-6 at 72 h in the
other three groups was lower than their baseline levels (Po0.05).
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Figure 6 | Effects of exchange transfusion on survival. Survival
time (day) was observed from the start of cecal ligation puncture
(CLP) to 7 days. EBP, extracorporeal blood purification group; EBP
to sham, sham animals received blood from the EBP animals;
Sham, sham group; Sham to EBP, EBP animals received blood
from the sham animals. P¼ 0.02, EBP vs. Sham; P¼ 0.045, Sham to
EBP vs. Sham; P¼ 0.047, EBP to sham vs. Sham.
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Figure 7 | Effects of extracorporeal blood purification (EBP) on
nuclear factor-jB (NF-jB) activation in circulating leukocytes.
Data are expressed as median (range, n¼ 7). EBP, extracorporeal
blood purification group; PMN, polymorphonuclear neutrophil;
Sham, sham group. *Po0.05, EBP vs. Sham.
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We started treatment at 18 h after CLP as the concentrations
of most mediators reach peak levels and the ligated cecum
begins to heal after 24 h.26
Given that the measured cytokine levels were not
decreased acutely, the exact mechanisms by which the EBP
resulted in late changes in these mediators, reduced organ
injury, and improved survival remain unclear. In our
previous studies, the improved survival after endotoxic
injection10 and severe CLP12 with treatment using a larger
adsorptive device were associated with the removal of
inflammatory cytokines. However, associations cannot
establish causality. In contrast, in this study, we were able
to demonstrate clinical effects despite the absence of early
cytokine changes, and therefore we can accept the null
hypothesis that clinical effects are not dependent on altering
cytokine levels. Similar to the effect of EBP on cytokines,
changes in markers of organ function were not apparent until
24–48 h after treatment. This was not due to differential
censoring as virtually no animals died before day 3. The
finding suggests that the effect of EBP by this scaled-down
device was not merely to remove cytokines for 4 h but to
influence downstream events.
It must be emphasized that the overall net effect on
survival in this study could be attributable to removal of
other mediators besides those that we measured. Indeed, we
cannot rule out simultaneous removal of different mediators,
which could possibly prevent the formation of other
biologically active substances, such as prostaglandins, leuko-
trienes, chemokines, or other cytokines, molecules that
up- or down-regulate membrane receptors, selectins, and
adhesion molecules.27 We have previously shown that EBP
results in reduced NF-kB DNA binding,10 and thus attenua-
tion of cytokines may have been because of reduced
production, as NF-kB DNA binding is a key intermediary
step leading to gene expression of several inflammatory
cytokines, including TNF and IL-6. Furthermore, patients
with sepsis not only face increased proinflammatory
cytokines, but also exhibit leukocyte hyporesponsiveness to
inflammatory stimuli. The general picture of the clinical
disorder is therefore better characterized by an immune
dysregulation than by a simple pro- or anti-inflammatory
disorder.28 Ronco et al.29 have suggested a peak concentration
hypothesis in which therapies may be effective if they can
cut the peaks of the concentrations of both pro- and anti-
inflammatory mediators, leading to the restoration of
immune homeostasis. It has been reported that some blood
purification techniques may regulate neutrophil function30
and improve monocyte function.31
To better elucidate the mechanism whereby EBP improved
organ function and survival, we conducted a second set of
experiments in which we performed exchange transfusions
between EBP and sham-treated rats immediately after
treatment. Our hypothesis was that benefits incurred by
EBP would be transferred to sham-treated animals, whereas
the ‘residual toxicity’ of the septic blood taken from sham-
treated animals would be transferred to the EBP-treated
animals. Our results were not as expected. Rather than
‘exchanging harm/benefit’, there was an ‘averaging’ of effect
with a near matching of late IL-6 levels (Figure 5) and
survival (Figure 6) between the two groups. We interpret
these findings to indicate that cytokine modulation per se was
only responsible for a portion of the benefit seen. In other
words, exchanging blood between EBP and sham-treated
animals resulted in plasma IL-6 concentrations only slightly
higher than animals treated with EBP and not exchanged, yet
survival was essentially midway between EBP and sham.
Conversely, sham-treated animals given exchange transfu-
sions with EBP-treated animals showed benefit in terms of
IL-6 levels and survival compared with sham treatment alone.
Taken together with the delayed effect on plasma cytokines,
HMGB-1, ALT, and creatinine, these results suggest that EBP
had effects other than cytokine modulation. We also carried
out additional studies to determine whether direct effects on
circulating immune effector cells are responsible for the
effects on survival seen in this model and found that NF-kB
activation in circulating PMNs was decreased with EBP.
NF-kB DNA binding is a crucial first step in the release of
multiple inflammatory cytokines.32 These results suggest that
EBP can function at the level of the circulating immune
effector cell and result in subsequent decreased cytokine
production. We speculate that this effect may be due to
changes in local cytokine concentrations within the device,
which are not manifested systemically.
Although the current sets of experiments more closely
represent human sepsis, there are important limitations.
First, we did not administer antibiotics to the animals in this
study because these therapies alter the inflammatory response
and may well have obscured any ‘signal’. In addition, the
administration of bactericidal antibiotics such as b-lactam
drugs may promote the release of lipopolysaccharide from
Gram-negative bacteria.33 Second, we recognize that rodent
sepsis is only a crude model of human sepsis, and that
multiple interventions effective in lower animals have not
translated into treatments for humans.21
In summary, EBP with CytoSorb titrated to a level below
which acute changes in cytokines are observed, and in a
clinically realistic model of human sepsis, attenuated late
inflammatory mediator activation induced by CLP sepsis and
improved organ function and 1-week survival. Exchange
transfusions between treated animals and shams transferred
part of the benefit/harm. This study suggests that survival
does not rely solely on changes in the usually measured
circulating cytokines. Thus, further study is needed to
better understand the mechanisms responsible for the effects
of EBP in sepsis and clinical trials, including seeking
alternative targets that need to be designed with these
findings in mind.
MATERIALS AND METHODS
Cecal ligation and puncture
Following approval by the Animal Care and Use Committee of the
University of Pittsburgh, we anesthetized 90 adult (24–28 weeks old,
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weight 450–550 g) male Sprague–Dawley rats with pentobarbital
sodium (40mg/kg intraperitoneally). Our CLP procedure was
modified (25% ligated length of cecum and 20-gauge needle, two-
puncture) in rats to induce less lethal sepsis compared with what we
have described previously.12 The abdomen was closed and 20ml/kg
lactated ringers were given subcutaneously as fluid resuscitation.
Topical anesthetic was applied to the surgical wound. Rats were
returned back to their cages and allowed food and water ad libitum.
At 18 h after CLP, the animals were re-anesthetized with pento-
barbital sodium. The femoral vein and the internal jugular vein were
isolated by dissection and cannulated with 1.27mm polyethylene-90
tubing for use of extracorporeal circulation.
Experimental protocol
At 18 h after CLP, these animals were randomly assigned to receive
either EBP (n¼ 30) or sham treatment (Sham, n¼ 30) for 4 h. The
extracorporeal circulation was driven by a mini pump (Fisher
Scientific, Pittsburgh, PA) from internal jugular vein to femoral vein
at a blood flow rate of 0.8–1.0ml/min. In the EBP group, the
extracorporeal circulation passed through a 1ml cartridge contain-
ing CytoSorb polymer beads (CytoSorbents). In the sham group, the
blood was passed through tubing with the same dead space as the
column. A volume of 20 unit/ml of heparin was used to prevent
coagulation in this circuit. After a 4-h intervention, the treatment
was stopped and the rats were observed for recovery, returned to the
animal facility, and given access to food and water. Survival time was
assessed up to 7 days. Another group (n¼ 30) with the same CLP
procedure but without extracorporeal circulation was used as the
control.
To explore the mechanism of the EBP, we conducted a separate set
of experiments involving another 40 animals. These animals were
exposed to the same CLP procedure and were randomized to receive
either EBP or sham treatment for 4 h just as before. At the end of
treatment, however, an exchange transfusion was carried out between
the EBP and sham-treated rats. This was accomplished by crossing the
circulation and pumping blood from each animal to the other
at a rate of 0.8–1.0ml/min for 30–45min. The maximum
exchange (B50%) would be reached within this time period based
on the following calculation: Cdonor¼ 0.5 [1þ exp(2Q/V t)];
Crecep¼ 0.5 [1exp(2Q/V t)], where Cdonor and Crecep
are the exchange percentage of donor and recipient, respectively,
Q (ml/min) is the flow rate, V (ml) is the effective circulating volume,
and t (min) is the exchange time. One animal died in the process of
setting up the extracorporeal circulation, and thus this pair of animals
was excluded. The remaining 38 animals were observed for 1 week.
An additional study was carried out to determine whether the
direct effects of EBP on circulating immune effector cells could
be demonstrated. A total of 14 rats (n¼ 7 each) were exposed to the
same CLP procedure and were randomized to receive either EBP or
sham treatment for 4 h. Blood was collected for NF-kB nuclear
binding in circulatory PMNs and monocytes. Liver and kidney were
harvested for histological observations.
Measurements and calculations
Blood (0.8ml) was drawn from the femoral line at 18 h after CLP
(immediately before treatment), after treatment, at 48 h, and at 72 h
after CLP. Blood samples were also obtained immediately after
exchange transfusion. The maximum blood loss for each animal was
o20% of total blood volume. We measured a panel of common
plasma cytokines (TNF-a, IL-1b, IL-6, and IL-10), and HMGB-1,
ALT, and creatinine.
Cytokines were measured with the multiplex bead-based
Luminex assays (Invitrogen, Camarillo, CA). These assays are
solid-phase protein assays that use spectrally encoded antibody-
conjugated beads as the solid support.34 Our assays were performed
in a 96-well plate format and analyzed with a Bio-Rad Bio-Plex 200
instrument, and the data were analyzed with the Bio-Plex Manager
4.0 software (Hercules, CA).
HMGB-1 was measured using an enzyme-linked immuno-
sorbent assay (Shino-Test Corporation, Chiba, Japan, measurement
range 0–80 ng/ml).35 ALT was determined using a LDH–NADH
coupled assay (Pointe Scientific, Canton, MI). Plasma creatinine
was measured with a creatinine enzymatic assay kit (BioVision
Technologies, Mountain View, CA).
The NF-kB DNA binding in circulating PMNs and monocytes
was measured with flow cytometry using a Cycletest Plus DNA
Reagent Kit (Becton Dickinson, Franklin Lakes, NJ) and anti–NF-kB
p65 antibodies and subtracting nonspecific binding using Isotype
control antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
Data were analyzed on the FCS Express software (De Novo Software,
Los Angeles, CA).
Liver and kidney sections were fixed in 10% neutral-buffered
formalin, dehydrated in graded anhydrous absolute ethanol, and
embedded in paraffin. Histological sections (5mm) were stained
with hematoxylin, eosin, and periodic acid-Schiff.
Statistical analysis
All numerical data were expressed as mean±standard error (s.e.m.).
Normal distribution of the data was confirmed by visual inspection
of result histograms, and all analyses were repeated after the data
were natural log (ln) transformed. Our primary analysis was
between CytoSorb and sham-treated animals and was based on
survival time as assessed by Kaplan–Meier, and OS in each group was
compared using Fisher’s exact (SPSS11, Chicago, IL). Plasma
cytokine concentrations, HMGB-1, ALT, and creatinine were
compared by examining the mean differences among and within
groups and analyzed by analysis of variance for repeated measures.
Data for NF-kB were expressed as median (ranges) and compared
with the Wilcoxon rank test. Po0.05 was considered to be of
significant difference.
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